Интраназальный флутиказона пропионат в фармакотерапии аллергического ринита

Keyphrases

• Pharmacotherapy 100%
• Rhinitis 100%
• Allergic Rhinitis 100%
• Fluticasone Propionate 100%
• Intranasal 100%
• Disease Control 66%
• General Practitioners 33%
• Primary Care 33%
• Quality of Life 33%
• Clinical Practice Guidelines 33%
• Specialty Care 33%
• Disease Symptoms 33%
• Nonallergic Rhinitis 33%
• Clinical Phenotype 33%
• Disease Burden 33%
• Pharmacist 33%
• Therapeutic Approaches 33%
• Immunologist 33%
• Outpatient Practice 33%
• Common Disease 33%
• National Society 33%
• Professional Community 33%
• Objective Measurement 33%
• Rhinitis Symptoms 33%
• Intranasal Corticosteroids 33%
• Step Therapy 33%
• First-line Therapy 33%
• Anti-inflammatory Drugs 33%
• Optimal Therapy 33%
• EAACI 33%
• Optimal Criteria 33%
• Professional Societies 33%
• Drug Class 33%
• Long-term Control 33%
• Interdisciplinary Interaction 33%
• Non-allergic 33%
• Severe Cases 33%
• Allergist 33%
• Innovative Therapies 33%
• Rhinosinusitis 33%
• Drug Choice 33%
• Socioeconomic Burden 33%

Medicine and Dentistry

• Disease 100%
• Drug Therapy 100%
• Allergic Rhinitis 100%
• Fluticasone Propionate 100%
• Rhinitis 80%
• Symptom 60%
• General Practitioner 20%
• Quality of Life 20%
• Vasomotor Rhinitis 20%
• Endotype 20%
• Antiinflammatory Agent 20%
• Clinical Guideline 20%
• Outpatient 20%
• Step Therapy 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Disease 100%
• Allergic Rhinitis 100%
• Fluticasone Propionate 100%
• Pharmacotherapy 100%
• Rhinitis 80%
• Symptom 60%
• Antiinflammatory Agent 20%
• Vasomotor Rhinitis 20%